Norwegian biotechnology firm Hofseth BioCare (HBC) posted yet another loss in the first quarter, falling even deeper into the red.

The group reported earnings before interest, taxes, depreciation and amortization (EBITDA) at a loss of NOK 18.8 million (€1.8 million/$2.3 million) widening from a loss of NOK 10.2 million (€1 million/$1.2 million) in the same quarter a year ago.

Australian kingfish producer Clean Seas completes $20 million placement
 Read more

Sales for the quarter were NOK 16.8